We are live on ! Find out more
EDSA icon

Edesa Biotech

17 hedge funds and large institutions have $350K invested in Edesa Biotech in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

1.02% more ownership

Funds ownership: 4.96%5.98% (+1%)

6% less funds holding

Funds holding: 1817 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

51% less capital invested

Capital invested by funds: $718K → $350K (-$368K)

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.22%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
3
Reduced
2
Closed
4
Calls
Puts
Net Calls
Net Calls Change

EDSA Hedge Fund Activity: Q4 2024 in Review

17 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q4 2024, worth a combined $350K — down 51% from $718K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of EDSA and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $114K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $50.4K sold.

  • 17 institutional investors held Edesa Biotech (EDSA) as of Q4 2024, down from 18 in Q3 2024.
  • Funds reported $350K of Edesa Biotech stock for Q4 2024, down 51% quarter-over-quarter.
  • 3 funds opened new Edesa Biotech positions in Q4 2024 and 4 closed out, a net change of -1 holder.
  • The largest Edesa Biotech buyer in Q4 2024 was Citadel Advisors, an estimated $114K added.
  • The largest Edesa Biotech seller in Q4 2024 was Dimensional Fund Advisors, an estimated $50.4K sold.

Based on aggregated 13F filings for Q4 2024.